Hantech Bio-Technology Co., Ltd. (1294) AI Stock Analysis

Hantech Bio-Technology Co., Ltd.

(TPEx:1294)

Select Model

Rating:67Neutral

Price Target:TWD 48.00▲(7.74% Upside)

Action:initiatedcoverage

Date:11/09/26

Hantech Bio-Technology scores moderately well overall. Its greatest strengths are a well-capitalized, low-leverage balance sheet and a convincing recovery into positive free cash flow with high-quality earnings conversion, supported by an inexpensive 10.5x P/E and a 6.77% dividend yield. Offsetting this, the share price is in a sustained downtrend, trading well below all key moving averages with negative MACD momentum, and the fundamental story has softened: revenue growth has slowed to the low single digits while three consecutive years of margin compression have pushed net income lower. Stabilizing margins and reaccelerating sales are the key catalysts needed to lift the score.

Positive Factors

Revenue GrowthRevenue expansion from 2022 through 2025, including 8.5% growth in 2025, indicates sustained demand and improving scale. Continued top-line growth gives the company a stronger base for absorbing costs, funding operations, and supporting earnings over the next several quarters.

Negative Factors

Margin CompressionThe decline in gross, EBIT, and net margins signals that recent revenue growth is not translating into profit at the earlier rate. If this pattern persists, higher costs, pricing pressure, or product-mix changes could limit earnings growth and weaken operating leverage.

Hantech Bio-Technology Co., Ltd. (1294) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.61B
Dividend Yield: 6.73%
Average Volume (3M): 19.69K
Price to Earnings (P/E): 10.4
Beta (1Y): 0.10
Revenue Growth: 20.43%
EPS Growth: 4.47%
Country: TW
Employees: 154
Sector: General
Sector Strength: 55
Industry: Packaged Foods

Hantech Bio-Technology Co., Ltd. Business Overview & Revenue Model

Company Description

Established in 2007 and headquartered in Yuanlin, Taiwan, Hantech Bio-Technology Co., Ltd. specializes in creating, producing, and distributing health products grounded in scientific research. The company distinguishes itself through its use of vario...

Hantech Bio-Technology Co., Ltd. Financial Statement Overview

Summary

A solid financial profile anchored by a conservative balance sheet (score 82): equity funds roughly 71% of assets and debt-to-equity has fallen to just 0.14 from 0.77 in 2023, giving ample flexibility. Cash flow (74) has turned a corner with a second consecutive year of positive free cash flow, up about 16% to NT$145 million and covering roughly 90% of net income. The weak link is the income statement (70): revenue growth has decelerated to about 4% after a doubling in 2023, and margins have compressed for three straight years (gross 44.9%, to 40.9%, to 36.5%; net 23.7% to 17.9%), pushing net income down to NT$139 million. Returns on the enlarged equity base have also slipped to 16.8% from 37.2% in 2023, though margins remain above typical packaged foods norms.

Income Statement

70Positive

Balance Sheet

82Very Positive

Cash Flow

74Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2021
Income Statement
Total Revenue	864.73M	778.54M	748.42M	625.14M	302.52M	240.29M
Gross Profit	310.04M	283.81M	305.74M	280.85M	126.63M	101.03M
EBITDA	215.15M	211.15M	232.09M	206.65M	78.52M	58.67M
Net Income	149.15M	139.08M	155.67M	148.12M	47.47M	32.56M
Balance Sheet
Total Assets	1.23B	1.17B	1.12B	930.94M	473.59M	375.65M
Cash, Cash Equivalents and Short-Term Investments	374.05M	339.38M	382.42M	167.09M	75.04M	86.41M
Total Debt	107.40M	113.28M	107.61M	307.09M	112.89M	139.68M
Total Liabilities	404.76M	334.10M	298.18M	529.56M	205.02M	197.74M
Stockholders Equity	819.21M	829.16M	817.78M	398.09M	266.89M	174.62M
Cash Flow
Free Cash Flow	120.59M	145.19M	125.36M	-105.31M	-20.44M	-35.93M
Operating Cash Flow	152.17M	160.63M	150.75M	191.91M	63.18M	44.39M
Investing Cash Flow	-142.97M	-107.40M	-25.38M	-295.63M	-84.07M	-79.76M
Financing Cash Flow	-176.90M	-186.28M	89.75M	195.83M	9.52M	40.40M

Hantech Bio-Technology Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:1294 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4111	76Outperform	TWD 1.71B	9.16	―	4.56%	5.33%	13.75%
TW:4911	72Outperform	TWD 1.74B	18.88	―	4.61%	-26.73%	-34.96%
TW:3164	71Outperform	TWD 1.44B	20.68	―	4.78%	1.32%	80.16%
TW:1294	67Neutral	TWD 1.62B	10.44	―	6.73%	20.43%	4.47%
TW:1295	59Neutral	TWD 1.57B	10.01	―	7.16%	-5.28%	-27.33%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4127	40Underperform	TWD 1.65B	23.58	―	―	52.12%	―

* General Sector Average

Performance Comparison

TW:1294 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:1294	Hantech Bio-Technology Co., Ltd.	44.55	-13.99	-23.89%
TW:1295	Synbio Tech Inc	41.80	-54.05	-56.39%
TW:3164	GenMont Biotech, Inc.	16.75	-0.96	-5.41%
TW:4111	Chi Sheng Pharma & Biotech Co., Ltd.	28.50	-0.44	-1.53%
TW:4127	Tien Liang Biotech Co., Ltd.	36.15	5.35	17.37%
TW:4911	G&E Herbal Biotechnology Co., Ltd.	25.30	-18.34	-42.03%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Hantech Bio-Technology Co., Ltd. AI Stock Analysis